. 2019 Oct 18;51(5):791–796. [Article in Chinese] doi: 10.19723/j.issn.1671-167X.2019.05.001

2.

rs1625895与DLBCL患者一线CHOP方案临床疗效的关系

Clinical response to CHOP therapy according to the genotype of rs1625895

Response	n	Genotype		χ²	P
Response	n	AA/AG, n(%)	GG, n(%)	χ²	P
DLBCL, diffuse large B-cell lymphoma; CHOP, cyclophosphoramide, doxorubicin, vincristine, prednisone; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OR, overall response.
Grouped by CR
PR+SD+PD	160	12(34.3)	148(43.1)	1.022	0.312
CR	218	23(65.7)	195(56.9)
Grouped by OR
PD+SD	65	6(17.1)	59(17.2)	0.000	0.993
OR(CR+PR)	313	29(82.9)	284(82.8)